Evidence-based position statement on the management of irritable bowel syndrome in North America

Am J Gastroenterol. 2002 Nov;97(11 Suppl):S1-5. doi: 10.1016/s0002-9270(02)05656-3.
No abstract available

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Antidepressive Agents, Tricyclic / therapeutic use
  • Antidiarrheals / therapeutic use
  • Behavior Therapy
  • Carbolines / therapeutic use
  • Cathartics / therapeutic use
  • Colonic Diseases, Functional* / diagnosis
  • Colonic Diseases, Functional* / epidemiology
  • Colonic Diseases, Functional* / physiopathology
  • Colonic Diseases, Functional* / therapy
  • Diagnosis, Differential
  • Evidence-Based Medicine*
  • Humans
  • Indoles / therapeutic use
  • Loperamide / therapeutic use
  • North America / epidemiology
  • Parasympatholytics / therapeutic use
  • Randomized Controlled Trials as Topic
  • Serotonin Antagonists / therapeutic use
  • Serotonin Receptor Agonists / therapeutic use
  • Severity of Illness Index

Substances

  • Antidepressive Agents, Tricyclic
  • Antidiarrheals
  • Carbolines
  • Cathartics
  • Indoles
  • Parasympatholytics
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • alosetron
  • tegaserod
  • Loperamide